[
  {
    "ts": null,
    "headline": "AbbVie (NYSE:ABBV) Showcases Oncology Innovations Amidst 6% Share Price Dip",
    "summary": "AbbVie (NYSE:ABBV) recently showcased significant advances in oncology, particularly with the introduction of new pipeline products like ABBV-969 and ABBV-514 at the AACR Annual Meeting 2025, reflecting a commitment to innovative cancer treatments. Despite a downturn in the broader market, with major indexes like the S&P 500 and Nasdaq seeing declines of 1% and 2% respectively, AbbVie managed an 11.86% increase in its stock price over the last quarter. This period also included critical...",
    "url": "https://finnhub.io/api/news?id=cf06f0a8086bcbd78df12095f61c52d049b78b12ef8edfcf8f433931598c3c18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743011166,
      "headline": "AbbVie (NYSE:ABBV) Showcases Oncology Innovations Amidst 6% Share Price Dip",
      "id": 133462064,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE:ABBV) recently showcased significant advances in oncology, particularly with the introduction of new pipeline products like ABBV-969 and ABBV-514 at the AACR Annual Meeting 2025, reflecting a commitment to innovative cancer treatments. Despite a downturn in the broader market, with major indexes like the S&P 500 and Nasdaq seeing declines of 1% and 2% respectively, AbbVie managed an 11.86% increase in its stock price over the last quarter. This period also included critical...",
      "url": "https://finnhub.io/api/news?id=cf06f0a8086bcbd78df12095f61c52d049b78b12ef8edfcf8f433931598c3c18"
    }
  },
  {
    "ts": null,
    "headline": "5 Reasons To Buy Regenxbio Right Now",
    "summary": "Regenxbio Inc. is ranked a Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and major buyout potential. Click for more on RGNX stock.",
    "url": "https://finnhub.io/api/news?id=8a40b480c8d306b7e091b768b67a23d4ebda58dfb202802efbf685da9ecf8ceb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742992278,
      "headline": "5 Reasons To Buy Regenxbio Right Now",
      "id": 133458187,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1452912285/image_1452912285.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Regenxbio Inc. is ranked a Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and major buyout potential. Click for more on RGNX stock.",
      "url": "https://finnhub.io/api/news?id=8a40b480c8d306b7e091b768b67a23d4ebda58dfb202802efbf685da9ecf8ceb"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025",
    "summary": "AbbVie (NYSE: ABBV) today announced that new data from its early oncology research will be showcased across multiple presentations at the upcoming American Association of Cancer Research (AACR) Annual Meeting, April 25-30, 2025. Presentations include data from novel investigational molecules, ABBV-969 and ABBV-514, across a range of hard-to-treat tumor types.1,2 Additionally, new insights on treatment resistance and novel biomarker identification based on real-world-data analyses are to be prese",
    "url": "https://finnhub.io/api/news?id=7fa113899fe7e1700a96d7d3e022505d702072f654f947b6922a0b572ab24ecb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742992200,
      "headline": "AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025",
      "id": 133457213,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced that new data from its early oncology research will be showcased across multiple presentations at the upcoming American Association of Cancer Research (AACR) Annual Meeting, April 25-30, 2025. Presentations include data from novel investigational molecules, ABBV-969 and ABBV-514, across a range of hard-to-treat tumor types.1,2 Additionally, new insights on treatment resistance and novel biomarker identification based on real-world-data analyses are to be prese",
      "url": "https://finnhub.io/api/news?id=7fa113899fe7e1700a96d7d3e022505d702072f654f947b6922a0b572ab24ecb"
    }
  },
  {
    "ts": null,
    "headline": "These Dividend Stocks Can Protect You From the Next Market Drop",
    "summary": "If markets remain rocky, either because of the Trump administration’s trade war or soft economic data, the aristocrats could continue to outperform.  “Our favorite defensive dividend strategy, dividend aristocrats, is a good place for investors to ‘hide’ in the event of an economic slowdown or recessionary environment,” he wrote.  The easiest way for investors to bet on long-time dividend payers is through an exchange-traded fund such as the  often known by its ticker, NOBL.",
    "url": "https://finnhub.io/api/news?id=77b152c5c71f212c219f0a7e98230f85625318e7f5c092208e667865b5b7f792",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742989320,
      "headline": "These Dividend Stocks Can Protect You From the Next Market Drop",
      "id": 133457214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "If markets remain rocky, either because of the Trump administration’s trade war or soft economic data, the aristocrats could continue to outperform.  “Our favorite defensive dividend strategy, dividend aristocrats, is a good place for investors to ‘hide’ in the event of an economic slowdown or recessionary environment,” he wrote.  The easiest way for investors to bet on long-time dividend payers is through an exchange-traded fund such as the  often known by its ticker, NOBL.",
      "url": "https://finnhub.io/api/news?id=77b152c5c71f212c219f0a7e98230f85625318e7f5c092208e667865b5b7f792"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income",
    "summary": "AbbVie's shares  dropped off a cliff  in November after it announced a clinical setback for emraclidine, an investigational schizophrenia treatment it got in an $8.7 billion acquisition.  Investors were worried the company spent nearly $9 billion for nothing, which is understandable.",
    "url": "https://finnhub.io/api/news?id=61fd4eaf3f5f7dd6253d719698b576de0bff90fb77dac19641bf03b882b4b2a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742985000,
      "headline": "2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income",
      "id": 133448346,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie's shares  dropped off a cliff  in November after it announced a clinical setback for emraclidine, an investigational schizophrenia treatment it got in an $8.7 billion acquisition.  Investors were worried the company spent nearly $9 billion for nothing, which is understandable.",
      "url": "https://finnhub.io/api/news?id=61fd4eaf3f5f7dd6253d719698b576de0bff90fb77dac19641bf03b882b4b2a8"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co.: Looming Patent Expiries For Key Drugs Weakens Longer-Term Outlook",
    "summary": ">40% of Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.",
    "url": "https://finnhub.io/api/news?id=9b4e78b04ae3afbd575bac37d78408711bc7628cc7a9328f60d9eaba4b50e894",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742981285,
      "headline": "Merck & Co.: Looming Patent Expiries For Key Drugs Weakens Longer-Term Outlook",
      "id": 133452861,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": ">40% of Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.",
      "url": "https://finnhub.io/api/news?id=9b4e78b04ae3afbd575bac37d78408711bc7628cc7a9328f60d9eaba4b50e894"
    }
  },
  {
    "ts": null,
    "headline": "Trump turbulence stalls large pharma and biotech deals, bankers say",
    "summary": "Large deals involvingpharmaceutical and biotech companies are stalling as executivesgrapple with mercurial White House economic policies that haveroiled markets and set off a global trade war,...",
    "url": "https://finnhub.io/api/news?id=51b6d241278b4a34ef7ec7535f7a50ed8fb01449e118162f7e01ba262e155fcc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742968800,
      "headline": "Trump turbulence stalls large pharma and biotech deals, bankers say",
      "id": 133447139,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Large deals involvingpharmaceutical and biotech companies are stalling as executivesgrapple with mercurial White House economic policies that haveroiled markets and set off a global trade war,...",
      "url": "https://finnhub.io/api/news?id=51b6d241278b4a34ef7ec7535f7a50ed8fb01449e118162f7e01ba262e155fcc"
    }
  }
]